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The EMBO Journal REFEREE REPORTS:
This is a very clearly written and concise paper and yet an extensive and in depth analysis of an important regulatory role for Runx1. The study exploits a large number of transgenic mouse lines to study, in vivo, the regulation of human CD34 in primitive murine hematopoietic cells. The results point to an important function for a distal regulatory element that binds Runx1. Intriguingly, and convincingly, the data obtained from 3C assay also reveal that Runx1 binding to this element is involved in looping of this enhancer/DRE to the CD34 promoter region. The study is elevated by the almost exclusive use of primary cells, its focus on hematopoietic stem cells and the application of 3C to primary hematopoietic cells. The conclusions are well substantiated and overall the study provides an important addition to the understanding of the function of a key transcription factor involved in regulation of primitive hematopoietic cells.
Referee #2:
RUNX proteins mediate interaction of distal regulatory elements in hematopoietic stem cells.
Summary:
In this paper, the authors show that expression of CD34 in long-term hematopoietic stem cells is governed by a distal regulatory element (DRE) within the human CD34 locus. This DRE was found to be necessary and sufficient for both expression and the hematopoietic reconstitutive capacity of SLAM+ LSK cells. They determine that while the DRE contains multiple Runx, GATA and E-Box binding sites, only the Runx sites were found to be required for proper DRE function. Runx1 protein was found to physically associate with the DRE. Expression of Runx1 in hematopoietic cells is required for expression of hCD34. The DRE was found to physically associate with the hCD34 promoter by chromatin looping, and cells in which hCD34 was actively being expressed showed elevated levels of enhancer-promoter association, suggesting this physical association is functionally relevant for transcription of hCD34. Runx1 binding sites within the DRE are important for its ability to interact with the hCD34 promoter. Together, the paper indicates that Runx1 is involved in hCD34 expression in hematopoietic cells by promoting the interaction of the promoter with a newlyidentified distal regulatory element.
Comments:
1. Supplementary Table 1 appears to be missing.
2. The manuscript is titled "RUNX proteins mediate interaction of distal regulatory elements in hematopoietic stem cells", however they only report the function of one of the RUNX family transcription factors, RUNX1, in the regulation of one distal regulatory element (CD34). Unless there is additional data about additional RUNX family proteins on the hematopoietic regulatory elements of additional genes, the title should be made to reflect the data presented.
3. The naming of populations hCD34low and hCD34low/+ is confusing. It would be good for the authors to further clarify the identity and isolation of these two populations.
4. This manuscript is a well-written, cohesive and succinct story showing a novel aspect of Runx1 function.
Referee #3:
Levantini et al investigate the regulation of human CD34. PAC transgenes of the human locus in transgenic mice show that a 'DRE' element +19kb is the only 3' element necessary for CD34 transgene expression in SLAM+ LSK cells. The authors should discuss this finding in light of their previous report of a more proximal 3' enhancer just downstream of the CD34 coding region.
Conditional deletion of Runx1 using Mx1Cre abolished CD34 transgene expression in SLAM+ LSK cells, indicating that Runx1 is required for CD34 transgene expression. This conclusion is strengthened further by the observation that mutations in Runx binding sites reduce the ability of the DRE to support CD34 expression from PAC transgenes. ChIP indicates binding of RUNX to DRE in CD34+ cord blood cells. Control ChIP experiments are required (e.g. in CD34-cells or in cells with PAC transgenes with mutated Runx binding sites).
3C analysis shows promoter/DRE interactions in CD34-expressing KG1a but not in CD34-HL60 cells, and a more limited analysis supports this suggestion in PAC transgenic SLAM+ LSK. The 3C standard deviations are unusually small, raising the question whether the replicates are independent 3C experiments or just PCR repeats. Supporting data are required to document the efficiency of the primers used on randomly religated templates and to demonstrate the efficiency of restriction enzyme digestion in KG1a and in HL60 cells.
This extensive body of work makes a very strong case that Runx1 binding to the 3' DRE is important for the expression of human CD34 PAC transgenes in SLAM+ LSK cells. Given the lack of evolutionary conservation of Runx sites 1, 3 and 4 and the authors' reasoning that mouse and human CD34 might be differentially regulated, it would seem necessary to demonstrate a role for Runx1 binding sites in the 3' DRE for CD34 expression in a relevant human cell type.
Why do the authors claim a specific role of DRE in the assembly of the transcriptional machinery (p12)? In the absence of experiments to characterize the assembly of the transcriptional machinery, this claim is unsupported and should be dropped.
The discussion should be shortened significantly. We have addressed all of the scientific comments below:
Reviewer #2:
Supplementary Table 1 appears to be missing.
We apologize if Table 1 was not available; it is included in the current submission.
The manuscript is titled "RUNX proteins mediate interaction of distal regulatory elements in hematopoietic stem cells", however they only report the function of one of the RUNX family transcription factors, RUNX1, in the regulation of one distal regulatory element (CD34). Unless there is additional data about additional RUNX family proteins on the hematopoietic regulatory elements of additional genes, the title should be made to reflect the data presented.
We adjusted the title accordingly to: "RUNX1 regulates the CD34 gene in hematopoietic stem cells by mediating interactions with a distal regulatory element".
The naming of populations hCD34low and hCD34low/+ is confusing. It would be good for the authors to further clarify the identity and isolation of these two populations.
We agree that this is confusing. We maintained the "hCD34 low " terminology unchanged, since this is commonly used notation. We renamed the previously-named "hCD34 low/+ " population "hCD34 intermediate" (hCD34 int ). In the legend of Figure 6 , this new nomenclature is adopted, and we explain that mice carrying construct F present an overall decreased hCD34 expression, as compared to mice carrying construct A, that can be subsequently divided into hCD34 low and hCD34 int , in accordance to the hCD34 gating strategy adopted throughout the study.
Reviewer #3:
The authors should discuss this finding in light of their previous report of a more proximal 3' enhancer just downstream of the CD34 coding region.
We have discussed the previous findings at the beginning of the discussion paragraph (page 13)
Control ChIP experiments are required (e.g. in CD34-cells or in cells with PAC transgenes with mutated Runx binding sites)
We have included ChIP data obtained on the hCD34 -cell line (HL60) utilized in this study for the 3C experiments, that show absence of Runx1 binding to the DRE element. The new data have been included in Figure 3 and in the Result section (page 9).
The 3C standard deviations are unusually small, raising the question whether the replicates are independent 3C experiments or just PCR repeats.
We performed two completely independent 3C experiments, not PCR repeats, for the HL60/KG1a cells described in Figure 5 . We have added this information in the Legend. We agree that the standard deviations are small, reflecting the experimental skills of Chris Hetherington, who has worked in my laboratory as a technician since the early 1990s.
Supporting data are required to document the efficiency of the primers used on randomly religated templates and to demonstrate the efficiency of restriction enzyme digestion in KG1a and in HL60 cells.
Efficiency of the primers utilized in the 3C experiments was tested on limiting dilutions (1:10, 1:100, 1:1000, and 1:10000) of the control library (PAC). The primer pair utilized to detect the interaction between the Promoter-DRE fragments showed an efficiency of 98.4%; all the remaining primer pairs (utilized to detect the interaction of the Promoter with the other 6 downstream fragments shown in Figure 5a ) showed a comparable efficiency of 96.4 +/-1.24 %.
The efficiency of restriction enzyme digestion in KG1a and HL60 cells was calculated according to the formula described by Hagège et al (Nature Protocols, 2007) in which the % restriction = 100-100/2^((Ct R -Ct C )D -(Ct R -Ct C )UND) Ct R and Ct C are the cycle thresholds (Ct values, i.e., the number of PCR cycles required to generate a threshold amount of PCR product) of the Restriction enzyme primers and the Control primers utilized to quantify the amount of DNA utilized per reaction. These primers have already been described in the Suppl. Material section.
The percentage of restriction appeared to be >90% at all the Hind3 junctions tested (surrounding the Promoter fragment, the DRE, and the other 6 downstream fragments preceding the DRE, and shown in Figure 5a ).
This information has all been included in the Supplementary information section (page S6).
It would seem necessary to demonstrate a role for Runx1 binding sites in the 3' DRE for CD34 expression in a relevant human cell type.
We agree with the reviewer that this is an excellent question, but unfortunately there is no easy way to measure the expression of the human CD34 transgene in a relevant human cell type, i.e., one expressing endogenous CD34. Since we had demonstrated that the 3C interaction is depending on Runx1, we decided instead to verify whether the same interaction was found in primary human CD34+ cells. Our 3C assays, performed on FACSpurified hCD34+ and hCD34-cord blood cells, were able to demonstrate that in a relevant human cell type, the frequency of promoter-DRE interaction is higher in hCD34+ cells as compared to hCD34-cells. This information has been included in the manuscript, in Figure  5d .
Why do the authors claim a specific role of DRE in the assembly of the transcriptional machinery (p12)? In the absence of experiments to characterize the assembly of the transcriptional machinery, this claim is unsupported and should be dropped.
Following the reviewer's suggestion we remove this phrase from the current manuscript.
7. The discussion should be shortened significantly.
Following the reviewer's suggestion and the editorial policy (no more than 55,000 characters) we have significantly shortened the discussion
In addition, we noticed a mistake in Figure 4 . We injected 0.8mg of PIPC, not 800mg/ml. So Figure 4 has been revised accordingly.
